CN102068718A - Preparation technology of nano arsenic trioxide/poly (lactic-co-glycolic acid) coated bracket - Google Patents
Preparation technology of nano arsenic trioxide/poly (lactic-co-glycolic acid) coated bracket Download PDFInfo
- Publication number
- CN102068718A CN102068718A CN2010105332999A CN201010533299A CN102068718A CN 102068718 A CN102068718 A CN 102068718A CN 2010105332999 A CN2010105332999 A CN 2010105332999A CN 201010533299 A CN201010533299 A CN 201010533299A CN 102068718 A CN102068718 A CN 102068718A
- Authority
- CN
- China
- Prior art keywords
- lactic
- glycolic acid
- arsenic trioxide
- liquid
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
A nano arsenic trioxide/poly (lactic-co-glycolic acid) coated bracket comprises a bracket body which is coated by a nano arsenic trioxide coating. The preparation method comprises: a certain amount of arsenic trioxide powder is fully dissolved in a sodium hydroxide solution, and the pH value is adjusted to form A solution; a certain amount of poly (lactic-co-glycolic acid) is dissolved in dichloromethane to form B solution; A solution is added to B solution, and the mixed solution is phacoemulsified to form C solution; polyvinyl alcohol is added to C solution to be ultrasonically dispersed in ice water, and D solution forms; D solution is stirred to form nano arsenic trioxide/poly (lactic-co-glycolic acid) colloidal solution, which is E solution; the stainless steel bare metal stent is ultrasonically cleaned, dried, then kept to stand in B solution; after dried the stent is kept to stand in E solution; the stent is kept in an oven to be dried after the E solution is removed, and the nano arsenic trioxide/poly (lactic-co-glycolic acid) coating stent forms at last.
Description
Technical field
The present invention relates to a kind of coating bracket and preparation technology thereof of anti-angiogenic restenosis, relate in particular to a kind of nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket and preparation technology thereof.
Background technology
Along with the change and the average life-time dilatation of people life style, the sickness rate of cardiovascular and cerebrovascular vessel and peripheral blood vessel occlusive disease obviously raises.Since Gruzentig finished the first routine percutaneous coronary intracavity forming (PTCA) in 1977, percutaneous transluminal angio plasty (PTA) has become the primary method that solves vascular occlusive disease, but the PTA postoperative still has the patient of 30-50% that restenosis takes place, and has influenced the late result of PTA.People adopt endovascular stent plasty (Endoluminal stenting) effectively to solve reinventing of PTA postoperative blood vessel retraction and blood vessel again afterwards, and restenosis rate has also dropped to about 18%.The mechanism of stent forming postoperative in-stent restenosis (ISR) except that blood vessel wall after vasodilation elastical retraction and the thrombosis, the hyper-proliferative of damage institute's inductive vascular smooth muscle cell (VSMC) has also also played crucial effect to the migration of inner membrance, so the propagation of prevention vascular smooth muscle cell becomes the key that solves the ISR generation with migration.On this basis, at the propagation of vascular smooth muscle cell, coating stent of medicine (DES) arises at the historic moment, at present, application be paclitaxel and rapamycin coating stent of medicine the most widely.Yet, though angiocarpy bracket can reduce the incidence rate of ISR effectively, but metal rack itself is as foreign body, stimulate the VSMC hypertrophy, can not prevent the generation of ISR fully, therefore select the good high molecular polymer of biocompatibility to cover rack surface, not only can overcome the bolt that causes that metal rack itself brings, quicken the process of blood vessel endotheliumization, and can be used as the carrier of anti-proliferative drugs, directly and the concentrated area arrives patient part, thus can avoid the toxic and side effects of whole body administration.
The characteristic of 1 lactic-co-glycolic acid (PLGA)
Lactic-co-glycolic acid (PLGA) is the copolymer of artificial synthetic polylactic acid (PLA) and polyglycolic acid (PGA), a large amount of experimentatioies has proved that PLGA is a kind of important biological medical polymer material with good biodegradability properties and biocompatibility, can not cause tangible inflammatory reaction, immunoreation and cell-cytotoxic reaction, and, be widely used in the research of drug delivery system through the material of FDA (FDA) approval as preparations such as injectable drug, nanoparticle, implants.Lactic-co-glycolic acid is passed through the catabolism of enzyme in vivo, final formation carbon dioxide and water are excreted, can not cause pollution, thereby be considered to the most rising Biodegradable polymer material, enjoy domestic and international concern the human internal environment.With the carrier of lactic-co-glycolic acid, can obtain the carrier material of different degradation rates by regulating lactic acid (LA) and the ratio of hydroxyacetic acid (GA) and the size of molecular weight in the lactic-co-glycolic acid molecule as the band medicine.Lactic-co-glycolic acid ratio commonly used has 80: 20,75: 25,50: 50 etc., be divided into different specifications again by the size of molecular weight.Ratio be 50: 50 PLGA because good hydrophilic property, and have suspendible dispersive property preferably, thereby be lactic-co-glycolic acid specification the most commonly used at present.
The antiproliferative effect of 2 arsenic trioxide
Arsenic trioxide (arsenic trioxide, As
2O
3) be commonly called as arsenicum, arsenious acid etc., be a kind of hypertoxic medicine, be again a kind of medicine of action range, as the history in existing more than 2400 year of medicinal application.1865, Lessauer once used oral FowlerShi liquid (also claiming Fowler's soln) treatment leukemia, and this is considered to use for the first time the cancer drug therapy malignant tumor.Harbin Medical University's first hospital report was used arsenic trioxide injection treatment acute promyelocytic leukemia (acute promyelocytic leukaemia in 1996, APL), the clinical good efficacy that obtains causes domestic and international colleague re-recognizing arsenic.After this have again many pieces of articles further report be the effect that the injection of main component has tangible anti-acute promyelocytic leukemia with the arsenic trioxide.The old Guoqiang of Ruijin Hospital Attached to Shanghai Medical Univ No.2 etc. has illustrated its mechanism of action from cell and molecular biology angle, U.S. food and drug administration also official approval with the scheme of arsenicum treatment acute promyelocytic leukemia.Therefore, people have therefrom obtained inspiration, begin the curative effect of further exploratory development arsenic trioxide to other multiple malignant tumor.At present existing lot of experiments the effect of acute promyelocytic leukemia to solid tumor and tumor cell, as liver HepG2 and SMMC-7721 cell, Gastric Cancer MGC-803 cell, neuroblastoma, people's squamous cell carcinoma of tongue, pulmonary carcinoma NCI-H69 cell, esophageal carcinoma EC8712 cell, pancreatic cancer cell, human bladder cancer BIU-87 cell etc. have proved that all arsenic has certain broad spectrum anticancer, its mechanism mainly is to suppress the effect of growth of tumour cell and inducing apoptosis of tumour cell, and multipath suppresses tumor proliferation to be shifted.
The application of 3 nanotechnologys in field of medicaments
Nanotechnology (Nano technology) is meant handling atom and molecule in 0.1～100nm space scale, material is processed, manufacturing has the product of specific function, or certain material is studied, and grasps the characteristics of motion of its atom and molecule and the new and high technology of characteristic.And many high-tech areas and even entire society have all been produced tremendous influence.After the notion of nanotechnology in last century is suggested, all show great application prospect in each fields such as material, metallurgy, chemical, medical science, environment, food.Along with continuous infiltration and the influence of nanosecond science and technology to the medical research field, this new term of Nano medication that has been born, thus caused the revolution far away of field of medicaments one field depth.Nano medication is meant with nanoscale high molecular nanometer grain (nano-particles, NP) or nanosphere (nano-spheres, NS), nanocapsule (nano-capsules, NC) etc. be carrier, the medicine of making after combining in a certain way with medicine, its particle diameter may surpass 100nm, but usually should be less than 500nm, and Nano medication also can be the nanoparticle of directly material medicine being processed into.
The Nano medication granule is little, surface reaction activity is high, the active center is many, catalytic efficiency is high, high adsorption capacity.Nano medication is compared with conventional medicine has following characteristics: (1) can increase drug solubility and degree of absorbing, and reduces drug dose, alleviates or eliminates toxic and side effects and save drug resource; (2) nano-particle can improve the absorption and the bioavailability of oral drugs such as protein, polypeptide class macromole as the carrier of biomacromolecule; (3) Nano medication can be realized slow release, controlled release and targeted therapy.Medicament slow release can continue to discharge medicine in a long time to reach long-acting after being meant medication; Medicine controlled releasing is meant that medicine can be in the given time initiatively and maintains in the valid density drug level long period by a certain speed constant release from preparation in effect organ or particular target tissue.At present, existing many pieces of articles report, behind the conventional medicament nanorize, drug effect improves greatly, has particularly shown sufficient superiority in antitumor research.
Summary of the invention
Body of the present invention provides a kind of arsenic trioxide that can prolong to effective acting time of vascular smooth muscle cell and have a preparation technology of nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket that slow release revises.
The present invention adopts following technical scheme to solve its technical problem:
The preparation method of a kind of nanometer arsenic trioxide of the present invention/lactic-co-glycolic acid coating bracket is characterized in that:
The preparation of step 1 nanometer arsenic trioxide/lactic-co-glycolic acid:
Getting 0.01-0.03g arsenic trioxide powder is fully dissolving in the sodium hydroxide solution of 1mmol/L in molar concentration, and with the hydrochloric acid of 1mmol/L pH value is transferred to 7.2-7.4, forms A liquid;
The 100mg lactic-co-glycolic acid is dissolved in the dichloromethane of 2ml, forms B liquid;
A liquid is added B liquid, and (volume ratio of A liquid and B liquid is 6-10: 1), ultrasonic emulsification 1min forms C liquid;
With the mass percent concentration of 12ml is that 2.25% polyvinyl alcohol adds in the C liquid of 60-100ml, uses supersonic generator that C liquid was carried out ultrasonic 90 seconds, disperses in frozen water, forms D liquid;
D liquid is risen to room temperature and stirs 3h with the 300r/min rotating speed, form nanometer arsenic trioxide/lactic-co-glycolic acid colloid solution, obtain E liquid, with arsenic trioxide/lactic-co-glycolic acid nanoparticle colloid solution in 4 ℃, 15000rpm, centrifugal 30min, abandoning supernatant, precipitation is removed the not free drug of parcel with distillation washing 3 times, vacuum freeze-drying gets lyophilized powder, and sealing is placed on 4 ℃ of preservations;
The preparation of step 2 nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket:
The stainless steel metal bare bracket was cleaned 3 minutes in the CQ50 supersonic generator, be statically placed in 24h in the above-mentioned B liquid after the oven dry, form the support of lactic-co-glycolic acid parcel, support with the lactic-co-glycolic acid parcel after the drying is statically placed in 48h in the E liquid, remove back dry 30min in 37 ℃ of baking boxs, form nanometer lactic-co-glycolic acid coating bracket at last.
Compared with prior art, the present invention has obtained following beneficial effect:
Employ new technology and prepared the novel form that lactic-co-glycolic acid is carried arsenic trioxide, nanometer arsenic trioxide/lactic-co-glycolic acid is a kind of comparatively ideal slow delivery formulations, can prolong the effective acting time of arsenic trioxide to vascular smooth muscle cell, external have certain cell growth inhibiting and an apoptosis-induced effect.Preliminary experimentation confirms that its propagation and migration to vascular smooth muscle cell has certain inhibitory action, and this novel pharmaceutical formulation will be expected to become the medication coat on coating stent of medicine surface from now on, for the clinical prevention in-stent restenosis provides new thinking and method.
1. after adopting the nanometer arsenic trioxide/lactic-co-glycolic acid ultra-sonic dispersion of biphase emulsification evaporation preparation, use transmission electron microscope (Fig. 1) and scanning electron microscope (Fig. 2) to observe respectively, be sub-circular, and certain electron density is arranged, be the spheroid that is dispersed in distribution.Calculate mean diameter by the CMIAS98A image analysis system, the mean diameter of the nanometer arsenic trioxide/lactic-co-glycolic acid of this Experiment Preparation is 90nm as can be known.Under the scanning electron microscope visual field, select several visuals field arbitrarily, with energy disperse spectroscopy nanometer arsenic trioxide/lactic-co-glycolic acid composition is analyzed (Fig. 3), as seen the composition that wherein contains arsenic, carbon and oxygen, the quality percentage composition (Wt%) of arsenic is 3.25%, atomic percentage conc (At%) is 0.72%, successfully prepares so can confirm nanometer arsenic trioxide/lactic-co-glycolic acid.Adopting the average drug loading of the nanometer arsenic trioxide/lactic-co-glycolic acid of atomic fluorescence spectrophotometer mensuration is 1.72%, and average envelop rate is 53.75%.With the normal saline is the external dynamic release that medium has been investigated nanometer arsenic trioxide/lactic-co-glycolic acid, reaches 72.37% during the cumulative release rate 4d of this medicine as calculated, reaches 96.82% during 15d, and progresses into plateau (Figure 13).
2. after the present invention adopts the dip coating preparation to carry nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket, under scanning electron microscope, observe naked metal support surface uneven (Fig. 4); The metal support surface of lactic-co-glycolic acid bag quilt obviously covers the membranaceous material of one deck, comparatively smooth (Fig. 7); The surface of nanometer arsenic trioxide/lactic-co-glycolic acid blood vessel coating bracket can be observed the parcel of membranaceous material, and the nano-scale particle (Figure 10) that contains certain electron density on the film, the mean diameter of this nano-particle is 92nm, with the mean diameter basically identical of our prepared nanometer arsenic trioxide/lactic-co-glycolic acid.Energy disperse spectroscopy has carried out component analysis to the metal rack (Fig. 9) of naked metal rack (Fig. 6), lactic-co-glycolic acid bag quilt and the metal rack (Figure 12) of nanometer arsenic trioxide/lactic-co-glycolic acid bag quilt respectively.Energy disperse spectroscopy shows that to the component analysis of nanometer arsenic trioxide/lactic-co-glycolic acid blood vessel coating bracket this support contains outside ferrum, nickel, chromium, carbon and the oxygen element, the quality percentage composition (Wt%) of arsenic is 12.57%, atomic percentage conc (At%) is 7.86%, confirmed the existence of arsenic, illustrated that nanometer arsenic trioxide/lactic-co-glycolic acid is coated in rack surface.
3. the arsenic content of nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket
The standard working curve of the arsenic of measuring with atomic fluorescence spectrophotometer is: I=3.737+13.097C, r=0.9995, wherein I is the analytic signal peak area, C is an arsenic concentration, after measured, the average drug loading of nanometer arsenic trioxide/lactic-co-glycolic acid is 1.72%, and average envelop rate is 53.75%.
4. the dynamic measurement result of nanometer arsenic trioxide/external rate of releasing drug of lactic-co-glycolic acid coating bracket
With the normal saline is the external dynamic release that medium has been investigated nanometer arsenic trioxide/lactic-co-glycolic acid, reaches 72.37% during the cumulative release rate 4d of this medicine as calculated, reaches 96.82% during 15d, and progresses into plateau (Figure 13).
5. nanometer arsenic trioxide/lactic-co-glycolic acid is to the influence of vascular endothelial cell proliferation and migration
MTT (methyl thiazolyl tetrazolium) body of laws is measured nanometer arsenic trioxide/lactic-co-glycolic acid outward former inhibitory action of being commissioned to train foster vascular smooth muscle cell proliferation is had time dependence and dose dependent.The time dependence lethal effect of nanometer arsenic trioxide/lactic-co-glycolic acid is always and continues to increase trend.After the flow cytometer result showed drug effect 48h and 72h, the apoptosis-induced effect of higher concentration nanometer arsenic trioxide/lactic-co-glycolic acid (18.71%, 29.9%) obviously was better than low concentration nanometer As2O3/PLGA (10.20%, 18.29%).5. Transwell cell migration experimental result shows that higher concentration nanometer arsenic trioxide/lactic-co-glycolic acid obviously is better than low concentration nanometer arsenic trioxide/lactic-co-glycolic acid (32.5%) to the inhibitory action (77.5%) of vascular smooth muscle cells migration.6. RT-PCR and Western blot show that nanometer arsenic trioxide/lactic-co-glycolic acid has inhibitory action to the Bcl-2 expression of gene of vascular smooth muscle cell, has facilitation (reduction of Bcl-2/Bax ratio) to the Bax expression of gene.And along with the increase Bcl-2/Bax ratio of drug level reduces more obvious (seeing Fig. 6,7,8,9).
Description of drawings
Fig. 1 is the nanometer arsenic trioxide transmission electron microscope photo that the present invention prepares.
Fig. 2 is the nanometer arsenic trioxide stereoscan photograph that the present invention prepares.
Fig. 3 is spectroscopy detection result's (annotate: the copper peak is due to the copper mesh) of nanometer arsenic trioxide.
Fig. 4 is electromicroscopic photograph of naked metal rack that the present invention makes.
Fig. 5 is another electromicroscopic photograph of the naked metal rack that makes of the present invention.
Fig. 6 be the naked metal that makes of the present invention can spectrogram.
Fig. 7 is that the lactic-co-glycolic acid bag for preparing of the present invention is by electromicroscopic photograph of metal rack.
Fig. 8 is that the lactic-co-glycolic acid bag is by another stereoscan photograph of metal rack.
Fig. 9 is that the lactic-co-glycolic acid bag is by the energy spectrogram of metal rack.
Figure 10 is an electromicroscopic photograph of the metal rack of nanometer arsenic trioxide/lactic-co-glycolic acid bag quilt of preparing of the present invention.
Figure 11 is another electromicroscopic photograph of the metal rack of nanometer arsenic trioxide/lactic-co-glycolic acid bag quilt.
Figure 12 is the metal rack EDS figure of nanometer arsenic trioxide/lactic-co-glycolic acid bag quilt.
Figure 13 is nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket cumulative release rate that the present invention prepares.
Figure 14 is light microscopic result (* 200 times) behind the negative control group processing vascular smooth muscle cell 96h.
Figure 15 is light microscopic result (* 200 times) behind 2umol/L nanometer arsenic trioxide/lactic-co-glycolic acid group processing vascular smooth muscle cell 96h.
Figure 16 is light microscopic result (* 200 times) behind 3 μ mol/L nanometer arsenic trioxide/lactic-co-glycolic acid group processing vascular smooth muscle cell 96h.
Figure 17 is light microscopic result (* 200 times) behind 4 μ mol/L nanometer arsenic trioxide/lactic-co-glycolic acid group processing vascular smooth muscle cell 96h.
Figure 18 is light microscopic result (* 200 times) behind 5 μ mol/L nanometer arsenic trioxide/lactic-co-glycolic acid group processing vascular smooth muscle cell 96h.
Figure 19 is the influence of negative control group to vascular smooth muscle cells migration.
Figure 20 is the influence of 1 μ mol/L nanometer arsenic trioxide/lactic-co-glycolic acid group to vascular smooth muscle cells migration.
Figure 21 is the influences of 3 μ mol/L nanometer arsenic trioxide/lactic-co-glycolic acid groups to vascular smooth muscle cells migration.
Figure 22 is the influences of 6 μ mol/L nanometer arsenic trioxide/lactic-co-glycolic acid groups to vascular smooth muscle cells migration.
After Figure 23 is variable concentrations nanometer arsenic trioxide/lactic-co-glycolic acid vasoactive smooth muscle cell 72h, the RT-PCR electrophoresis result.
After Figure 24 is variable concentrations nanometer arsenic trioxide/lactic-co-glycolic acid vasoactive smooth muscle cell 72h, western-blot trace result.
The specific embodiment
A kind of nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket comprises: rack body, the external packets of rack body is covered with nanometer arsenic trioxide/lactic-co-glycolic acid.
The preparation method of a kind of nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket,
The preparation of step 1 nanometer arsenic trioxide/lactic-co-glycolic acid:
Getting 0.01-0.03g arsenic trioxide powder is fully dissolving in the sodium hydroxide solution of 1mmol/L in molar concentration, and with the hydrochloric acid of 1mmol/L pH value is transferred to 7.2-7.4, forms A liquid;
The 100mg lactic-co-glycolic acid is dissolved in the dichloromethane of 2ml, forms B liquid;
A liquid is added in the B liquid, and wherein, the volume ratio of A liquid and B liquid is 6-10: 1, and present embodiment can be selected 6: 1,7: 1 or 10: 1, and ultrasonic emulsification 1min forms C liquid;
With the mass percent concentration of 12ml is that 2.25% polyvinyl alcohol adds in the C liquid of 60-100ml, uses supersonic generator that C liquid was carried out ultrasonic 90 seconds, disperses in frozen water, forms D liquid, and wherein, the model of supersonic generator is CQ50;
D liquid is risen to room temperature and stirs 3h with the 300r/min rotating speed, form nanometer arsenic trioxide/lactic-co-glycolic acid colloid solution, obtain E liquid, with arsenic trioxide/lactic-co-glycolic acid nanoparticle colloid solution in 4 ℃, 15000rpm, centrifugal 30min, abandoning supernatant, precipitation is removed the not free drug of parcel with distillation washing 3 times, vacuum freeze-drying gets lyophilized powder, and sealing is placed on 4 ℃ of preservations;
The preparation of step 2 nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket:
The stainless steel metal bare bracket was cleaned 3 minutes in the CQ50 supersonic generator, be statically placed in 24h in the above-mentioned B liquid after the oven dry, form the support of lactic-co-glycolic acid parcel, support with the lactic-co-glycolic acid parcel after the drying is statically placed in 48h in the E liquid, remove back dry 30min in 37 ℃ of baking boxs, form nanometer lactic-co-glycolic acid coating bracket at last.
Present embodiment system nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket, perusal is except that surface-coated skim sample material, more naked metal rack does not have significant change.
Claims (1)
1. the preparation technology of nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket is characterized in that,
The preparation of step 1 nanometer arsenic trioxide/lactic-co-glycolic acid:
Getting 0.01-0.03g arsenic trioxide powder is fully dissolving in the sodium hydroxide solution of 1mmol/L in molar concentration, and with the hydrochloric acid of 1mmol/L pH value is transferred to 7.2-7.4, forms A liquid;
The 100mg lactic-co-glycolic acid is dissolved in the dichloromethane of 2ml, forms B liquid;
A liquid is added in the B liquid (wherein, the volume ratio of A liquid and B liquid is 6-10:1), and ultrasonic emulsification 1min forms C liquid;
With the mass percent concentration of 12ml is that 2.25% polyvinyl alcohol adds in the C liquid of 60-100ml, uses supersonic generator that C liquid was carried out ultrasonic 90 seconds, disperses in frozen water, forms D liquid;
D liquid is risen to room temperature and stirs 3h with the 300r/min rotating speed, form nanometer arsenic trioxide/lactic-co-glycolic acid colloid solution, obtain E liquid, with arsenic trioxide/lactic-co-glycolic acid nanoparticle colloid solution in 4 ℃, 15000rpm, centrifugal 30min, abandoning supernatant, precipitation is removed the not free drug of parcel with distillation washing 3 times, vacuum freeze-drying gets lyophilized powder, and sealing is placed on 4 ℃ of preservations;
The preparation of step 2 nanometer arsenic trioxide/lactic-co-glycolic acid coating bracket:
The stainless steel metal bare bracket was cleaned 3 minutes in the CQ50 supersonic generator, be statically placed in 24h in the above-mentioned B liquid after the oven dry, form the support of lactic-co-glycolic acid parcel, support with the lactic-co-glycolic acid parcel after the drying is statically placed in 48h in the E liquid, remove back dry 30min in 37 ℃ of baking boxs, form nanometer lactic-co-glycolic acid coating bracket at last.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010533299 CN102068718B (en) | 2010-11-05 | 2010-11-05 | Preparation technology of nano arsenic trioxide/poly (lactic-co-glycolic acid) coated bracket |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010533299 CN102068718B (en) | 2010-11-05 | 2010-11-05 | Preparation technology of nano arsenic trioxide/poly (lactic-co-glycolic acid) coated bracket |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102068718A true CN102068718A (en) | 2011-05-25 |
| CN102068718B CN102068718B (en) | 2013-12-25 |
Family
ID=44027599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010533299 Expired - Fee Related CN102068718B (en) | 2010-11-05 | 2010-11-05 | Preparation technology of nano arsenic trioxide/poly (lactic-co-glycolic acid) coated bracket |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102068718B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110075365A (en) * | 2019-04-30 | 2019-08-02 | 上海市第六人民医院 | A kind of hydrogel containing hydrophilic medicament takes bolt bracket preparation method |
| CN111329880A (en) * | 2019-12-11 | 2020-06-26 | 浙江中医药大学 | Transition metal compound-coated arsenic trioxide nanoparticles and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0970711A2 (en) * | 1998-06-30 | 2000-01-12 | Ethicon, Inc. | Process for coating stents |
| CN101161300A (en) * | 2007-11-27 | 2008-04-16 | 北京美中双和医疗器械有限公司 | Arsenic trioxide medicament elution bracket |
| CN101214397A (en) * | 2007-12-29 | 2008-07-09 | 杨巍 | Medicament elution bracket for promoting esoderma repair and preventing vascular restenosis |
-
2010
- 2010-11-05 CN CN 201010533299 patent/CN102068718B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0970711A2 (en) * | 1998-06-30 | 2000-01-12 | Ethicon, Inc. | Process for coating stents |
| CN101161300A (en) * | 2007-11-27 | 2008-04-16 | 北京美中双和医疗器械有限公司 | Arsenic trioxide medicament elution bracket |
| CN101214397A (en) * | 2007-12-29 | 2008-07-09 | 杨巍 | Medicament elution bracket for promoting esoderma repair and preventing vascular restenosis |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110075365A (en) * | 2019-04-30 | 2019-08-02 | 上海市第六人民医院 | A kind of hydrogel containing hydrophilic medicament takes bolt bracket preparation method |
| CN110075365B (en) * | 2019-04-30 | 2022-02-01 | 上海市第六人民医院 | Hydrogel thrombus removal stent entrapping hydrophilic drugs and preparation method thereof |
| CN111329880A (en) * | 2019-12-11 | 2020-06-26 | 浙江中医药大学 | Transition metal compound-coated arsenic trioxide nanoparticles and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102068718B (en) | 2013-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ali et al. | Noble metals based bimetallic and trimetallic nanoparticles: controlled synthesis, antimicrobial and anticancer applications | |
| Cabuzu et al. | Biomedical applications of gold nanoparticles | |
| Shen et al. | A novel carboxymethyl chitosan-based folate/Fe3O4/CdTe nanoparticle for targeted drug delivery and cell imaging | |
| Silva et al. | Aerosolizable gold nano-in-micro dry powder formulations for theragnosis and lung delivery | |
| He et al. | Localized multidrug co-delivery by injectable self-crosslinking hydrogel for synergistic combinational chemotherapy | |
| Qin et al. | Self-assembly of metal–phenolic networks as functional coatings for preparation of antioxidant, antimicrobial, and pH-sensitive-modified starch nanoparticles | |
| Nivethaa et al. | A comparative study of 5-Fluorouracil release from chitosan/silver and chitosan/silver/MWCNT nanocomposites and their cytotoxicity towards MCF-7 | |
| Najafabadi et al. | pH-sensitive ameliorated quercetin delivery using graphene oxide nanocarriers coated with potential anticancer gelatin-polyvinylpyrrolidone nanoemulsion with bitter almond oil | |
| CN112546027B (en) | Fat-soluble pigment-loaded nanoparticle and preparation method thereof | |
| Shi et al. | Sonochemical preparation of folic acid-decorated reductive-responsive ε-poly-L-lysine-based microcapsules for targeted drug delivery and reductive-triggered release | |
| Dizaj et al. | The application of nanomaterials in cardiovascular diseases: A review on drugs and devices | |
| Niazvand et al. | An overview of the development of composites containing Mg and Zn for drug delivery | |
| Huang et al. | Design and application of dextran carrier | |
| Ehsanimehr et al. | Synthesis of pH-sensitive nanocarriers based on polyacrylamide grafted nanocrystalline cellulose for targeted drug delivery to folate receptor in breast cancer cells | |
| CN103566415A (en) | Human body blood vessel implant with coatings on two surfaces and manufacturing method thereof | |
| Moghaddam et al. | Fabrication of carboxymethyl chitosan nanoparticles to deliver paclitaxel for melanoma treatment | |
| Chen et al. | Can photothermal post-operative cancer treatment be induced by a thermal trigger? | |
| US20080300296A1 (en) | Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith | |
| CN102068718B (en) | Preparation technology of nano arsenic trioxide/poly (lactic-co-glycolic acid) coated bracket | |
| Gowda et al. | Nanosponges as an emerging platform for cancer treatment and diagnosis | |
| Pourmadadi et al. | Synthesis and characterization of biological macromolecules double emulsion based on carboxymethylcellulose/gelatin hydrogel incorporated with ZIF-8 as metal organic frameworks for sustained anti-cancer drug release | |
| Zhao et al. | Preparation and characterization of paclitaxel loaded SF/PLLA-PEG-PLLA nanoparticles via solution-enhanced dispersion by supercritical CO 2 | |
| Wang et al. | Fucoidan-mediated anisotropic calcium carbonate nanorods of pH-responsive drug release for antitumor therapy | |
| CN106913579A (en) | Hyaluronic acid targeting pH sensitive medicaments carriers and its preparation method and application | |
| Ruman et al. | Synthesis and Characterization of Chitosan-Based Nanodelivery Systems to Enhance the Anticancer Effect of Sorafenib Drug in Hepatocellular Carcinoma and Colorectal Adenocarcinoma Cells. Nanomaterials 2021, 11, 497 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131225 Termination date: 20161105 |